Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 26, 2026Case Reports in Oncological MedicineOpen Access

Mitigating Severe Ribociclib‐Hepatotoxicity With Corticosteroids

View Full Paper
Ask AI
Bookmark
Share

Authors

JWJulie WilliamsonMPMaria PletnevaRKRebecca G. Kim

Discussion

Loading...

Member takes

Overview

Case report demonstrates corticosteroids improve liver function in severe ribociclib hepatotoxicity, highlighting treatment options.

Key Points

  • To explore the management of severe ribociclib-induced hepatotoxicity when medication cessation is insufficient.
  • Presented a case of a woman with HR+ HER2− breast cancer and hepatotoxicity after ribociclib and anastrozole treatment.
  • Evaluated liver function and determined the cause as drug-induced liver injury from ribociclib.
  • Administered a long course of corticosteroids to mitigate hepatotoxicity.
  • The patient had grade 2 AST and ALT elevation that progressed to Grade 4 hepatotoxicity despite holding ribociclib.
  • Initiation of corticosteroids resulted in a remarkable response and resolution of transaminitis.
  • Suggests consideration of corticosteroids for severe hepatotoxicity from CDK4/6 inhibitors after stopping the drug.

Cite This Study

Williamson et al. (2026) studied this question.

synapsesocial.com/papers/69edacbd4a46254e215b465bhttps://doi.org/10.1155/crom/4222126
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract PS1-03-24: Real-world evaluation of hepatotoxicity during treatment with ribociclib2026
  2. 2Risk factors of hepatotoxicity with ribociclib in hormone receptor-positive breast cancer2026
  3. 3Real-world evidence of ribociclib-induced hepatotoxicity in patients with breast cancer: a multi-center experience2025 · 1 citations
  4. 4Management of hepatotoxicity associated with CDK4/6 inhibitors and rechallenge strategies in metastatic hormone-positive, HER2-negative breast cancer2025 · 1 citations
  5. 5Analysis of the Frequency and Associated Factors of Skin Toxicity in Patients Receiving Ribociclib-Based Therapy for Metastatic Breast Cancer2026